Method of treating psma-expressing cancers
AssigneeEndocyte, Inc.
InventorsChristopher Paul LEAMON, Richard MESSMANN
Life of this patent
Estimating the term…
Abstract
The present invention relates to combinations for use and methods of treating cancers that express prostate specific membrane antigen (PSMA). In particular, the invention provides novel therapies based on the combination of a PSMA therapeutic agent, such as radiolabeled Compound I, and immuno-oncology (I-O) therapeutic agents, wherein said I-O therapeutic agents are selected from the group consisting of LAG-3 inhibitors, TIM-3 inhibitors, GITR agonists, TGF-β inhibitors, IL15/IL-15RA complex, PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors.
Claims20
A method of treating a PSMA expressing cancer in a subject, comprising administering to the subject a combination of a PD-1 inhibitor, a CTLA-4 inhibitor, and a compound of Formula Ia (Compound Ia)
- wherein Compound Ia is radiolabeled.
Dependencies are inferred from the claim text.